Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide

Clin J Gastroenterol. 2014 Jun;7(3):255-9. doi: 10.1007/s12328-014-0471-9. Epub 2014 Apr 9.

Abstract

Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic glucagonoma. We report a 46-year-old Japanese woman with glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic glucagonoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Female
  • Glucagonoma / complications*
  • Humans
  • Middle Aged
  • Necrolytic Migratory Erythema / drug therapy*
  • Necrolytic Migratory Erythema / etiology*
  • Octreotide / therapeutic use*
  • Pancreatic Neoplasms / etiology*
  • Remission Induction
  • Time Factors

Substances

  • Antineoplastic Agents, Hormonal
  • Octreotide